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Abstract
Objective: Identifying risk factors for cancer treatment-related acute exacerbations (AEs) of idio-
pathic interstitial pneumonia (IIP) in patients with lung cancer.
Methods: We retrospectively reviewed clinical records of 98 patients with concurrent lung cancer
and IIPs diagnosed and treated at the Sapporo Medical University Hospital from January 2010 to
December 2014.
Results: Of the 98 patients with concurrent lung cancer and IIPs, 14 patients (14.3%) had AEs. A total
of 10 patients died. The univariate analysis revealed that the patients with idiopathic pulmonary
fibrosis (IPF) or usual interstitial pneumonia (UIP) patterns on chest computed tomography (CT)
had significantly higher rates of AE than those with non-IPF or non-UIP patterns, respectively.
Further, those with a reduced percentage of forced vital capacity (%FVC) predictive values or
elevated Krebs von den Lungen-6 (KL-6) presented significantly higher rates of AE. Our multivariate
analysis identified that UIP pattern on chest CT and each 10% decrease in %FVC were significant
independent risk factors for AEs. Of the 14 patients who experienced AEs, 10 cases were associated
with cancer treatment. The treatment-specific incidences were 3/40 (7.5%) for surgery, 5/50 (10.0%)
for chemotherapy, and 2/26 (7.7%) for radiation therapy. After comparing the AE incidences in
55 cases receiving one treatment (monotherapy group) and in 29 cases receiving two types of
treatment or more (multitherapy group), we found no significant differences.
Conclusions: Chest CT UIP patterns and reduced %FVC are independent risk factors for AE. More-
over, AE incidence did not increase in the multitherapy group compared with the monotherapy
group.
Key words: lung cancer, idiopathic interstitial pneumonia, acute exacerbation
Introduction
Idiopathic interstitial pneumonia (IIP) are a serious health complica-
tion associated with high mortality covering nine different clinical
types of unknown cause, including idiopathic pulmonary fibrosis
(IPF), which has the poorest prognosis and accounts for over 50%
of all IIPs (1). Mortality and morbidity are high in patients with IIPs
because of respiratory failure that leads to chronic deterioration, or
acute exacerbations (AEs), and frequent onset of concurrent lung
cancer. Particularly, 10–30% of patients with IPF have concurrent
lung cancer (2–7). Patients with IPF have a 7–14-fold higher risk
of lung cancer than people without IPF, indicating that IPF is an
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associated with an extremely poor prognosis with a mortality rate
for the first onset at 50–80% (9–10). A study of patients with IPF in
Japan and Korea reported that the most common cause of death was
AE (40–46%) (3,11).
In patients with concurrent lung cancer and IIPs, cancer treatment
may cause AEs, and the reported incidences of AE associated with
surgery, chemotherapy, or radiotherapy range from 9.3% to 42.9%
(12–19). Therefore, the choice between the life-prolonging benefit of
cancer treatment and the risk of AE onset is a challenging problem
in clinical practice. Generally, pulmonologists, at a tertiary care
hospital, specialize in diagnosing the interstitial lung diseases (ILDs)
and IIPs; however, medical oncologists, radiotherapists or respiratory
surgeons oversee lung cancer treatment. Therefore, it is possible that
many lung cancer patients with concurrent IIPs are not regarded as
candidates for lung cancer treatment due to the risk of treatment-
related AEs, and safe treatment for this group has not been estab-
lished. The current American guidelines for lung cancer treatment
National Comprehensive Cancer Network/American Society of Clin-
ical Oncology (NCCN/ASCO) do not provide information regarding
patients treated with concurrent ILDs (20–22). In Japan, there is
an accumulation of experience regarding patients with concurrent
lung cancer and IIPs because pulmonologists themselves diagnose
and treat such patients. The Japanese Respiratory Society published
‘Statement on Interstitial Pneumonia Combined Lung Cancer’ and
providing guidance and calling for the construction of evidence (23).
Although multitherapies that combine surgery, chemotherapy, and
radiotherapy for lung cancer treatment are recommended, there has
not been a detailed study on whether AE risk differs between patients
undergoing monotherapy and those undergoing multitherapy.
It is hoped that lung cancer patients with IIPs should be treated
effectively with low risk. AE caused by lung cancer treatment is the
most serious adverse event compared to patients without IIP. To iden-
tify AE risk factors related to cancer treatment, we retrospectively
analyzed IIP patients who underwent lung cancer treatment at a
tertiary care hospital.
Patients and methods
We retrospectively selected patients who had complicated ILDs with
lung cancer and were treated at Sapporo Medical University Hospital
in Japan from January 2010 to December 2014. We excluded patients
with identifiable ILD complications, such as those with collagen
disease, pneumoconiosis and hypersensitivity pneumonitis. We clas-
sified IIPs following the international multidisciplinary classification
of 2013 (1).
Three pulmonologists used chest high-resolution computed
tomographies (HRCTs) from the time of lung cancer diagnosis to
the time of retrospective study review. Then, they independently
classified the cases into two groups based on the image patterns:
one for patients with UIP patterns (UIP pattern group) and one
for patients with image patterns, which were either possible UIP or
inconsistent with UIP (non-UIP pattern group). The pulmonologists
based their diagnoses on the American Thoracic. Society/European
Respiratory Society/Japanese Respiratory Society/Latin American
Thoracic Society (ATS/ERS/JRS/ALAT) diagnostic criteria (24).
The three pulmonologists interpreted the CT images using both
5-mm and 1-mm thicknesses and concerted the cases with divergent
diagnoses after a further discussion on the diagnoses. For this study,
we used the definition of AE advocated by Collard et al. (25) to
conform to the diagnostic criteria of AEs. The diagnostic criteria
involve examining the development of dyspnea or its unexplained
worsening within the last 30 days. Moreover, HRCT is used to
verify new bilateral ground-glass abnormalities and/or consolidation
superimposed on existing interstitial shadows. The final requirement
is the exclusion of other etiologies including infection, left-sided heart
failure, pulmonary embolism, and identifiable causes of acute lung
injury.
We defined cancer treatment-related AEs as those occurring
within 4 weeks from the time of surgical operation, or within
8 weeks from the end of chemotherapy, or within 6 months from
the start of radiation therapy (15,16,26). We grouped into patients
who experienced AEs (AE-IIP group) and those who did not (Sta-
ble IIP group) during the observation period. We collected data
based on age, sex, smoking history, performance status (PS), chest
CT findings, histological type and clinical stage of lung cancer,
surfactant protein (SP)-A, SP-D, KL-6, forced vital capacity (FVC),
diffusing capacity of the lung for carbon monoxide (DLCO) and
treatment contents. In addition, we grouped the patients into a
monotherapy group (patients underwent a single cancer treatment
of surgery, chemotherapy, or radiation therapy), or a multitherapy
group (patients underwent two or more treatments simultaneously
or sequentially), and we analyzed the risk of AE in both groups.
For statistical analysis, we performed the univariate analysis using
the chi-square test or Fisher’s exact test, and the multivariate analysis
using logistic regression. We considered P < 0.05 as statistically
significant. We performed all the statistical analyses using the JMP
version 13 software (SAS Institute, Cary, NC, USA). The institutional
review board of the Sapporo Medical University Hospital approved
this study (approval number 272–91; ref. 2015/12/11).
Results
Patient background
The clinical characteristics of all subject patients, the AE-IIP group
and the Stable IIP group are shown in Table 1. The study included
98 lung cancer patients with IIPs as the underlying disease. Their
mean age was 70 years (IQR, 65–76), 90.8% were men, 96.9%
were current or previous smokers and 80.6% were PS ≤ 1. The
histological types of lung cancer were adenocarcinoma in 41 patients
(41.8%), squamous cell carcinoma in 34 patients (34.7%) and small-
cell carcinoma in 11 patients (11.2%). More than half (n = 57) of
the patients had stages IA-IIIB (UICC-TNM classification, 7th edn).
The IIP disease types were IPF in 52 patients (53.1%), nonspecific
interstitial pneumonia (NSIP) in three patients (3.0%), and unclassifi-
able IIPs in 43 patients (43.9%). CT imaging patterns were UIP in 46
patients (46.9%) and non-UIP patterns in 52 patients (53.1%). Con-
current pulmonary emphysema was found in 52 patients (53.1%).
Of the IPF patients, Pirfenidone has been administered to the three
patients. All 98 patients received either surgical therapy, chemother-
apy, radiotherapy or a combination of these, or received best sup-
portive care.
Risk of AE in patients with IIPs
Among the 98 patients with concurrent lung cancer and IIP, AEs
occurred in 14 patients (14.3%) and 10 patients died. There were
nine cases (one autopsy case) of imaging findings following the
diffuse alveolar damage (DAD) pattern, with the outcome of all cases
being death. There were four cases of imaging findings following the
organizing pneumonia (OP) pattern, for all of which the outcome
was survival. In addition, there was one case of a DAD + OP pattern
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Table 1. Patient characteristics
n (%) or Median (IQR; Range)
Total AE-IIP Stable IIP P
n 98 14 84
Age 70 (65–76; 48–87) 69 (65.8–74.3; 62–80) 70.5 (65–76; 48–87) 0.8668
Gender 0.3502
Male 89 (90.8) 14 (100) 75 (89.3)
Female 9 (9.2) 0 (0) 9 (10.7)
Ever smoker 95 (96.9) 14 (100) 81 (96.4) 1
Pack-years 54.5 (42–80; 0–188) 60.5 (44.3–80; 35–117) 53 (41.3–80.8; 0–145) 0.4835
ECOG · PS 1
0–1 79 (80.6) 11 (78.6) 68 (80.9)
2–4 19 (19.4) 3 (21.4) 16 (19.1)
Histology 0.4996
Adenocarcinoma 41 (41.8) 4 (28.6) 37 (44.1)
Squamous cell carcinoma 34 (34.7) 6 (42.9) 28 (33.3)
Small-cell carcinoma 11 (11.2) 1 (7.1) 10 (11.9)
Others 12 (12.3) 3 (21.4) 9 (10.7)
Clinical stages 0.3835
IIIB 57 (58.2) 4 (28.6) 53 (63.1)
IV 41 (41.8) 10 (71.4) 31 (36.9)
IIP type 0.0464∗
IPF 52 (53.1) 11 (78.6) 41 (48.8)
NSIP 3 (3.0) 0 (0) 3 (3.6)
Unclassifiable 43 (43.9) 3 (21.4) 40 (47.6)
HRCT
UIP pattern 46 (46.9) 11 (78.6) 35 (58.3) 0.0183
Non-UIP pattern 52 (53.1) 3 (21.4) 49 (41.7)
Emphysema 52 (53.1) 5 (35.7) 47 (56.0) 0.2471
Non-emphysema 46 (46.9) 9 (64.3) 37 (44.0)
SP-A (ng/ml) 48.5 (39.5–68.8; 10.7–145) 46 (41.8–67.8; 23.3–83.1) 49.5 (38.9–68.8; 10.7–145) 0.8927
SP-D (ng/ml) 99.6 (71.7–172; 10–735) 150 (72.6–288.5; 28–452) 96 (71–150; 10–735) 0.1969
KL-6 (U/ml) 516 (326–818; 113–3600) 881.5 (451–1246; 129–3600) 482 (312–792; 113–1790) 0.0436
%FVC (%) 98.3 (82.6–116.7; 50.3–153.4) 79.7 (74.2–94.5; 58–112.5) 103.2 (90.2–117.9; 50.3–153.4) 0.005
%DLco (%) 54.1 (42.5–66.7; 15.9–81.9) 53.3 (46.6–68.6; 23.3–74.5) 54.1 (41.8–66.2; 15.9–81.9) 0.963
IQR, interquartile range; AE-IIP, acute exacerbation of idiopathic interstitial pneumonia; stable IIP, non-exacerbation of idiopathic interstitial pneumonia;
ECOG, Eastern Cooperative Oncology Group; PS, performance status; IPF, idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial pneumonia; HRCT, high-
resolution computed tomography; UIP, usual interstitial pneumonia; SP-A, surfactant protein A; SP-D, surfactant protein D; KL-6, sialylated carbohydrate antigen
Krebs von den Lungen-6; %FVC, focal vital capacity % predicted; %DLco, diffusing capacity of the lung carbon monoxide % predicted.
∗Fisher’s exact test (IPF vs NSIP and Unclassifiable).
The univariate analysis revealed that the patients with IPF
(P = 0.0464) or UIP patterns (P = 0.0183) had significantly higher
rates of AE than those with non-IPF or non-UIP patterns, respectively.
We found AEs in five patients out of 52 patients with pulmonary
emphysema (9.6%) and nine patients experienced AEs out of 46
patients with non-pulmonary emphysema (19.6%). However, no
significant difference was found in the frequency between the two
groups (P = 0.2471). Further, those with reduced FVC% predictive
values (P = 0.005) or elevated KL-6 (P = 0.0436) presented
significantly higher rates of AE (Table 1). Moreover, our receiver
operating characteristic (ROC) curve analysis revealed that the
%FVC cutoff values were 91.2% (sensitivity, 0.727; specificity,
0.726; and AUC, 0.773), and KL-6 cutoff values were 820 U/ml
(sensitivity, 0.583; specificity, 0.823; and AUC, 0.712) (Fig. 1).
In the multivariable analysis in this research, due to there being
a low number of AE occurrences, we statistically limited the inde-
pendent variables used. By changing the independent variables that
were significant in univariable analysis or independent variables that
were considered to be important, three models were constructed.
On univariate analysis of IIP type, IPF was significant but was
excluded from multivariate analysis due to the strong correlation to
UIP patterns on CT. Consistently in all models, UIP patterns on CT
and each 10% decrease in %FVC were independent risk factors for
AE (Table 2).
Treatment details for AE patients
The treatment for lung cancer is presented in Table 3. Aggressive
or palliative treatment was administered to 84 patients, and best
supportive care was administered to 14 patients. We observed
treatment-related AEs in 10 patients (10.2%), with 30 day/90 day
mortality rates of 60%/60%, respectively. The median time from the
end of treatment to the onset of AE is 23 days (range: 5–69 days).
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Table 2. Multivariate analysis of risk factors associated with AE in patients with concurrent lung cancer and IIPs
Variable Odds ratio 95% CI P (Wald test) P (likelihood ratio test)
Model 1
UIP pattern on HRCT 15.01 1.37–164.16 0.0265 0.0068
%FVC (per 10% decreased) 1.7 1.06–2.71 0.0277 0.0119
%DLco (per 10% decreased) 0.88 0.43–1.80 0.1118 0.0917
Model 2
UIP pattern on HRCT 15.56 1.25–193.09 0.0326 0.0068
%FVC (per 10% decreased) 1.67 1.03–2.69 0.0365 0.0119
%DLco (per 10% decreased) 0.63 0.36–1.12 0.1179 0.0955
KL-6 (per 100 U/ml increased) 0.9 0.76–1.06 0.2226 0.1396
Model 3
UIP pattern on HRCT 15.67 1.43–171.79 0.0243 0.0061
%FVC (per 10% decreased) 1.7 1.06–2.73 0.029 0.0127
%DLco (per 10% decreased) 0.62 0.35–1.09 0.0994 0.0776
ECOG-PS (2–4) 0.45 0.03–7.73 0.5847 0.5925
IIP, idiopathic interstitial pneumonia.
Table 3. Selection of treatment
Treatment n (%)
Total 98 (100)
Surgery alone 26 (26.5)
Chemotherapy alone 22 (22.5)
Radiotherapy alone 7 (7.1)
Surgery + chemotherapy 9 (9.2)
Surgery + radiotherapy 1 (1.0)
Surgery + chemotherapy+radiotherapy 4 (4.1)
Chemotherapy + radiotherapy 15 (15.3)
Best supportive care 14 (14.3)
Table 4. Causes of AE
















patients (4.1%), with 30-day/90-day mortality rates of 50%/50%.
Antecedent infections may have triggered the exacerbations in
three of the patients and a complication of a procedure involving
transbronchial biopsy triggered the exacerbation in the other patient
(Table 4).
Surgery. A total of 40 patients underwent surgery, including surgery
alone and surgery combined with other therapies (lobectomy in
34 patients, segmentectomy in four patients and partial resection
in two patients). Among these patients, three (7.5%) experienced
AEs after surgery (Table 4) and all had lobectomies. In one patient,
surgical stress was thought to be the AE trigger. In the remaining
two patients, AEs occurred after postoperative complications (an
infection caused by postoperative bronchial stump fistula in one
patient, and postoperative pneumonia and pyothorax in the other).
Chemotherapy. A total of 50 patients received chemotherapy, either
alone or in combination with other therapies. AEs occurred during
chemotherapy in five patients (10.0%) (Table 4). AEs occurred in
four patients given chemotherapy alone, and one patient experienced
an AE during chemotherapy, after receiving combined radiotherapy.
We calculated the frequencies of AE onsets according to
chemotherapy regimen (Table 5). Thirteen chemotherapy regimens
were administered a total of 67 times. Thirty-three patients were
treated with the first regimen alone and 17 patients were treated with
the second regimen after the first regimen. In nine patients given VP-
16-based chemotherapy, we found no AEs. We found AEs in one out
of 19 patients (5.3%) given pemetrexed (PEM)-based chemotherapy,
and in one out of 18 patients (5.6%) given paclitaxel (PTX)-based
chemotherapy. However, AEs occurred in two out of 12 patients
(16.7%) given vinorelbine (VNR)-based chemotherapy, indicating a
relatively higher AE incidence. We attributed the AE to the presence
of an underlying severe infection with febrile neutropenia in one of
these two patients. Additionally, we found AE onset in one out of
nine patients (11.1%), given docetaxel (DOC)-based chemotherapy.
In comparison between combination chemotherapy and single-agent
chemotherapy, AEs occurred in two out of 54 patients (3.7%) given
platinum-based doublet chemotherapy and three of 13 patients
(23.1%) given single-agent chemotherapy.
Radiotherapy. Radiotherapy, including radiotherapy alone and
radiotherapy combined with other therapies, was administered
to 27 patients. A total of six patients received irradiation of the
primary pulmonary lesion, two patients with stage IA disease
received stereotactic irradiation therapy aiming for a radical cure
and two patients with stage IIIA disease received a combined
chemoradiation therapy using fractionated irradiation. In addition,
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PEM-based 19 1 (5.3)
CDDP + PEM 3 1
CBDCA + PEM + BEV 1 0
CBDCA + PEM 14 0
PEM alone 1 0
PTX-based 18 1 (5.6)
CBDCA + PTX 13 1
CBDCA + nabPTX 5 0
VNR-based 12 2 (16.7)
CDDP + VNR 7 0
CBDCA + VNR 1 0
VNR alone 4 2
DOC-based 9 1 (11.1)
CDDP + DOC 1 0
DOC alone 8 1
VP-16-based 9 0
CDDP + VP-16 1 0
CBDCA + VP-16 8 0
PEM, pemetrexed; CDDP, cisplatin; CBDCA, carboplatin; BEV, beva-
cizumab; PTX, paclitaxel; nabPTX, nanoparticle albumin-bound paclitaxel;
VNR, vinorelbine; DOC, docetaxel; VP-16, etoposide.
fractionated irradiation method only. None of these six patients who
received irradiation of the primary lesion experienced AE. Palliative
irradiation, not including the primary lesion in the irradiation
field, was administered to 21 patients (14 patients with the lung
included in the irradiation field and seven patients without). During
radiotherapy, two patients experienced AEs (7.4%) (Table 4). These
two patients received palliative irradiation for metastatic lesions in
the thoracic vertebrae and their lungs were included in the irradiation
field.
Comparison between the monotherapy and
multitherapy groups (Table 6)
The monotherapy and multitherapy groups consisted of 55 patients
and 29 patients, respectively. In the monotherapy group, six patients
experienced AEs associated with lung cancer treatment (10.9%), and
among them, five died (9.1%). In the multitherapy group, we found
AEs in four patients (13.8%); and among them, two died (6.9%).
However, we found no significant difference between the two groups
in terms of the incidence of AE (P = 0.7314, Fisher’s exact test).
Discussion
Lung cancer patients with IIPs are exposed to the risk of AE asso-
ciated with cancer treatment. This seems to be a major factor
in hesitation among doctors to provide cancer treatment for such
patients and tends to lead to missed opportunities for improvement.
This hesitancy appears to stem from the fact that patients with IIPs
are excluded from clinical trials for the development of anticancer
drugs and thus there is little evidence of safety. Lung cancer treatment
including surgery, chemotherapy and radiotherapy is provided by
monotherapy or a combination of therapies, and treatment decisions
are based on disease stage, recurrence and metastasis status. When
planning treatment for lung cancer in patients with IIPs, it is very
important to accurately estimate the risk of developing AE for
each treatment, and it is possible to provide the best treatment
options in each case. In this study, we clarified risk factors of AE
onset in the treatment of lung cancer in IIP patients and found no
significant difference in the incidence of AE between monotherapy
and multitherapy.
A comparison between the AE-IIP and Stable IIP groups high-
lighted statistically significant differences in the patterns of HRCT
images and %FVC values. Further, these variables were identified as
independent risk factors for AE. Kenmotsu et al. (15) reported that
when assessing the risk of chemotherapy-related AE of interstitial
pneumonia (IP), a UIP pattern displayed on CT images was a risk
factor for AE with an odds ratio of 6.98. Our results confirm these
findings with an even higher odds ratio of 15.01 (Model 1; 95% CI,
1.37–164.16). Therefore, the presence of a UIP pattern on a CT image
is an extremely important risk factor signaling the likely presence of
AE. In a retrospective study by Enomoto et al. (27) among patients
who received chemotherapy, a low baseline %FVC value was iden-
tified as a risk factor for AE, and the odds ratio for IP exacerbation
for each 1% increase in FVC was 0.97 (95% CI, 0.94–0.99). We
also examined the odds ratio for each 10% decrease in FVC by
creating a dummy variable and reported an odds ratio of 1.7 (Model
1; 95% CI, 1.03–2.69). Accordingly, the risk of AE-IP appears to
increase with a decrease in FVC. We calculated an FVC cutoff value
of 91.2% for AE based on a ROC curve. The value of 91.2% was
within the normal range, but this may be because 52 (53.1%) of 98
patients included also had concurrent pulmonary emphysema, which
may mask the decrease in FVC. A higher incidence of lung cancer
has been reported among patients with concurrent emphysema than
among those with fibrosis alone (28). Moreover, the incidence of lung
cancer in combined with pulmonary fibrosis and emphysema is high
at 46.8% (29). Our univariate analysis results indicate that among
several candidate biomarkers, KL-6 might be useful to predict the risk
of AE. Ohshimo et al. (30) conducted a prospective study on patients
with IPF and reported that elevated KL-6 level was a risk factor for
AE with a cutoff value of 1300 U/ml (30). However, compared with
that study, our study reported a lower cutoff value of 820 U/ml. Our
study subjects also had lung cancer and received treatment for this
disease, which may have further lowered the cutoff value. However,
in our multivariate analysis result, KL-6 was not an independent risk
factor. The significant correlation between %FVC and KL-6 levels
in this study (ρ = −0.319; P = 0.014) may be one reason for the
dropout of KL-6 in multivariate analysis. All these findings together
suggest that patients showing a non-UIP pattern, a %FVC ≥ 91.2%
and a KL-6 level < 820 U/ml, can receive treatment for lung cancer
with a significant level of safety than other patients.
In a large-scale retrospective study, Sato et al. (16) reported that
the incidence of AE caused by surgery was 9.3%, and in our study,
AEs were observed in three out of the 40 patients who underwent
surgery (7.5%), which was a roughly comparable incidence. All of
the patients who developed AE had undergone lobectomy. No studies
have focused on reductive surgery in concurrent lung cancer and IIPs,
but it is possible that the extent of pneumonectomy correlates with
the AE onset. There is only sparse evidence for recommending a regi-
men of lung cancer chemotherapy for patients with IP including IIPs.
A small population, prospective study of carboplatin [cyclobutane-
1,2-dicarboxylic acid (CBDCA)] + PTX for patients with concurrent
non–small-cell lung cancer and IP showed that AE occurred in one of
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Table 6. AE caused by cancer treatment in the monotherapy group and multitherapy group
n (%) or Median (IQR; Range)
Monotherapy Multitherapy P
n 55 29
Treatment-related AE 6 (10.9) 4 (13.8) 0.7314
Stable 49 (89.1) 25 (86.2)
UIP pattern 26 (47.2) 15 (51.7) 0.8191
KL-6 (U/ml) 566.5 (353–818; 207–3600) 440 (319–840.5; 113–1670) 0.4397
%FVC (%) 98.3 (80.2–116.9; 50.3–153.4) 103.7 (88.6–121.9; 69.9–142) 0.5378
16 for patients with small-cell lung cancer and IP showed evidence
of AE in one out of 17 patients (5.9%) (18). In our study, consistent
with previous studies, the frequency of AE onsets was relatively low
on PTX-based regimens and VP-16 based regimens. In addition, it
was shown that the frequency of AE onsets was also low on PEM-
based regimens. Thus, PTX, VP-16 and PEM-based chemotherapies
can be administered to IPF patients with relative safety. Furthermore,
in the comparison between combination chemotherapy and single-
agent chemotherapy, the frequency of AE onset was high in single-
agent chemotherapy. This result indicates that the risk of AE onset
is elevated in patients judged to require single-agent chemotherapy
rather than combination chemotherapy due to deterioration of the
general condition. Taking into consideration the therapeutic effect
of single-agent chemotherapy and the risk of AE onset, it might be
recommended not to perform chemotherapy for patients who could
not undergo combination chemotherapy. In general, most patients
with concurrent lung cancer and IIPs do not receive irradiation.
Therefore, few studies have focused on treatment. Our results showed
that six patients who received irradiation of the primary lesion
suffered no AEs; however, we observed AEs in two out of seven
patients (28.6%) who received palliative irradiation in the lung area.
All of the six patients who received irradiation of the primary lesions
had combined pulmonary fibrosis, emphysema and mild fibrotic
lesions on chest CT, and thus stereotactic radiation therapy was
selected for all six patients. Based on our results, particular care is
required for irradiation of the lung fields, even in cases of palliative
irradiation.
We found no significant differences in AE incidences between
the monotherapy and the multitherapy groups. This shows that
both groups are comparable in terms of AE risk. For patients for
whom monotherapy is not the cause of AE, the risk of AE may not
increase even if treatment is successively changed. For patients with
concurrent lung cancer and IIPs, studies on monotherapies and on
multitherapies are warranted.
We found that most patients diagnosed with non-UIP patterns of
HRCT did not undergo histopathological diagnosis by surgical lung
biopsy, which accounted for 44 of 55 patients (84.6%) diagnosed
with unclassifiable IIPs. It may be that in many cases of concurrent
lung cancer, diagnostic examinations such as surgical lung biopsy
cannot be sufficiently performed, which leads to an increase in the
rate of unclassifiable IIPs according to the international classification.
Further, it is possible that non-IIP patients, such as those with
chronic hypersensitivity pneumonitis or ILD preceding connective
tissue disease, could have been categorized as having unclassifiable
IIPs due to insufficient pathological evidence. However, this study is
likely an accurate representation of current clinical realities.
One of the limitations of this study is that ours was a single-
center study, with few regimens for each respective chemotherapy,
and insufficient radiotherapy sessions. A second limitation has to
do with the diagnosis of AE based on CT findings alone, given that
histopathological diagnoses are not obtained in most cases. Although
we excluded infections based on a bacteriological examination, as
well as heart failure based on physical findings and echocardio-
graphy, we were unable to entirely exclude respiratory infections,
pulmonary embolisms or left heart failures. From the evaluation of
the clinical course and progress on imaging, the diagnoses of AE were
reliable.
Conclusion
In patients with lung cancer and IIPs, we found that UIP patterns
on chest CT and reduced %FVC on respiratory function tests were
risk factors for AE onset. The odds ratio for the association between
AE and UIP pattern was particularly strong. Moreover, our results
suggest that patients who received monotherapy with no AEs are
unlikely to experience AEs when combined with multitherapy.
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